Novartis holds workshop to help eliminate malaria in Africa

Novartis encourages malaria elimination in Africa
Novartis encourages malaria elimination in Africa | Courtesy of

Novartis recently held the 14th annual National Malaria Control Program (NMCP) Best Practice Sharing Workshop involving more than 35 countries in Africa in order to encourage the nation to eliminate malaria from its borders.

Africa currently faces a major turning point in battling malaria. The meeting was called in order for malaria experts from more than 35 African countries to exchange and discuss innovative strategies and tools to eliminate malaria.

"This discussion could not have come at a better time since we in the Southern African Development Community region are already advanced in the elimination program having earmarked eight countries in this region as pilots for the elimination campaign," Hon. Dr. Nazira Abdula, Minister for Health, Mozambique, said.

"Novartis is proud to provide this unique platform," Dr. Linus Igwemezie, Head of the Novartis Malaria Initiative, said. "These meetings have been designed for NMCP members by NCMP members, to develop new ideas and strategies to achieve elimination of this deadly disease."

"These NMCP meetings are important platforms to share best practice across the continent and drive progress,” Dr. Simon Kunene, NMCP Head Swaziland, said. “Kenya for example has made significant improvements in the quality of malaria case management since the implementation of the new policy that requires diagnostic testing prior to treatment. The same applies to the entire Southern African Development Community which has tremendously improved case management after harmonizing treatment protocols in the region. In my own country Swaziland, we have made great progress towards malaria elimination through improved disease surveillance, a critical area since it helps program managers focus their resources."

Organizations in this Story


Want to get notified whenever we write about Novartis ?
Next time we write about Novartis, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.